219 related articles for article (PubMed ID: 25109837)
1. Suppressed Krüppel‑like factor 17 expression induces tumor proliferation, metastasis and a poor prognosis in papillary thyroid carcinoma.
Ye WC; Gao L; Huang J; Fang XM; Xie G
Mol Med Rep; 2014 Oct; 10(4):2087-92. PubMed ID: 25109837
[TBL] [Abstract][Full Text] [Related]
2. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
3. ALDH5A1 acts as a tumour promoter and has a prognostic impact in papillary thyroid carcinoma.
Deng XY; Gan XX; Feng JH; Cai WS; Wang XQ; Shen L; Luo HT; Chen Z; Guo M; Cao J; Shen F; Xu B
Cell Biochem Funct; 2021 Mar; 39(2):317-325. PubMed ID: 32881051
[TBL] [Abstract][Full Text] [Related]
4. RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer.
Fan C; Wang W; Jin J; Yu Z; Xin X
Cell Physiol Biochem; 2017; 41(3):1229-1239. PubMed ID: 28268222
[TBL] [Abstract][Full Text] [Related]
5. miR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1.
Han J; Zhang M; Nie C; Jia J; Wang F; Yu J; Bi W; Liu B; Sheng R; He G; Kong L; Zheng L; Pang R; Ding Z; Chen L; Guan Q; Pan S; Meng X; Xu J; Liu L; Zhang J
Cell Death Dis; 2019 Feb; 10(3):195. PubMed ID: 30814512
[TBL] [Abstract][Full Text] [Related]
6. Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma.
Liu FY; Deng YL; Li Y; Zeng D; Zhou ZZ; Tian DA; Liu M
Med Oncol; 2013 Mar; 30(1):425. PubMed ID: 23325444
[TBL] [Abstract][Full Text] [Related]
7. miR-199a-5p inhibits the progression of papillary thyroid carcinoma by targeting SNAI1.
Ma S; Jia W; Ni S
Biochem Biophys Res Commun; 2018 Feb; 497(1):181-186. PubMed ID: 29427661
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells.
Song HM; Luo Y; Li DF; Wei CK; Hua KY; Song JL; Xu H; Maskey N; Fang L
Int J Clin Exp Pathol; 2015; 8(9):9889-900. PubMed ID: 26617698
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of long non-coding RNA NR_036575.1 contributes to the proliferation and migration of papillary thyroid cancer.
Sun W; Lan X; Wang Z; Dong W; He L; Zhang T; Zhang H
Med Oncol; 2016 Sep; 33(9):102. PubMed ID: 27510368
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-150 targets Rho-associated protein kinase 1 to inhibit cell proliferation, migration and invasion in papillary thyroid carcinoma.
Cheng L; Zhou R; Chen M; Feng L; Li H
Mol Med Rep; 2017 Aug; 16(2):2217-2224. PubMed ID: 28656254
[TBL] [Abstract][Full Text] [Related]
11. ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1).
Mato E; González C; Moral A; Pérez JI; Bell O; Lerma E; de Leiva A
J Mol Endocrinol; 2014 Jun; 52(3):289-300. PubMed ID: 24643400
[TBL] [Abstract][Full Text] [Related]
12. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
Ma Y; Qin H; Cui Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
[TBL] [Abstract][Full Text] [Related]
13. Platelet derived growth factor receptor alpha mediates nodal metastases in papillary thyroid cancer by driving the epithelial-mesenchymal transition.
Ekpe-Adewuyi E; Lopez-Campistrous A; Tang X; Brindley DN; McMullen TP
Oncotarget; 2016 Dec; 7(50):83684-83700. PubMed ID: 27845909
[TBL] [Abstract][Full Text] [Related]
14. RasGRP3 controls cell proliferation and migration in papillary thyroid cancer by regulating the Akt-MDM2 pathway.
Qiu W; Xia X; Qiu Z; Guo M; Yang Z
Gene; 2017 Oct; 633():35-41. PubMed ID: 28864115
[TBL] [Abstract][Full Text] [Related]
15. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
16. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
17. Downregulation of serum DKK-1 predicts poor prognosis in patients with papillary thyroid cancer.
Zhao YP; Wang W; Wang XH; Xu Y; Wang Y; Dong ZF; Zhang JJ
Genet Mol Res; 2015 Dec; 14(4):18886-94. PubMed ID: 26782539
[TBL] [Abstract][Full Text] [Related]
18. CHK2 Promotes Anoikis and is Associated with the Progression of Papillary Thyroid Cancer.
Zhao W; Chen S; Hou X; Chen G; Zhao Y
Cell Physiol Biochem; 2018; 45(4):1590-1602. PubMed ID: 29486482
[TBL] [Abstract][Full Text] [Related]
19. The involvement of CXCR7 in modulating the progression of papillary thyroid carcinoma.
Liu Z; Yang L; Teng X; Zhang H; Guan H
J Surg Res; 2014 Oct; 191(2):379-88. PubMed ID: 24814201
[TBL] [Abstract][Full Text] [Related]
20. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.
Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM
Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
